A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.9999 USD 2.13%
Market Cap: 95.3m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Assertio Holdings Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Capital Expenditures
-$247k
CAGR 3-Years
N/A
CAGR 5-Years
39%
CAGR 10-Years
16%
Johnson & Johnson
NYSE:JNJ
Capital Expenditures
-$4.4B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Capital Expenditures
-$1.2B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Pfizer Inc
NYSE:PFE
Capital Expenditures
-$3.2B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Capital Expenditures
-$3.4B
CAGR 3-Years
10%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Capital Expenditures
-$8.3B
CAGR 3-Years
-53%
CAGR 5-Years
-38%
CAGR 10-Years
-18%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
95.4m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.5618 USD
Undervaluation 36%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Capital Expenditures?
Capital Expenditures
-247k USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Capital Expenditures amounts to -247k USD.

What is Assertio Holdings Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
16%

Over the last year, the Capital Expenditures growth was 98%.

Back to Top